On September 18, 2025, Canada’s Drug Agency (CDA) launched its new strategy to improve the appropriate prescribing and use of prescription medications in Canada. The strategy, titled “A Prescription for Action: A Pan-Canadian Strategy for Advancing the Appropriate Use of Prescription Medications,” provides a 5-year plan to foster a unified national approach that promotes safer, more effective medication use and strengthens health system sustainability.
The strategy sets out four strategic priorities:
- Partnerships and Program Development: Develop, enhance, and implement appropriate use initiatives with partners across Canada.
- Connect: Strengthen networks and provide comprehensive information about appropriate use.
- Strategy and Policy: Develop evidence-informed advice and recommendations for decision-makers about the adoption and implementation of appropriate use policies and strategic initiatives.
- Evaluation and Reporting: Assess project outcomes and communicate impact clearly.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Pharmaceutical and Life Sciences Sector Task Force submits final report to the Ministers of Health and Industry
On July 24, 2026, the Pharmaceutical and Life Sciences Sector Task Force (the “Task Force”) published its final report to the Ministers of Health and Industry pursuant to a mandate to (i) explore inno...Read More -
Canada’s Drug Agency: guidance document on use of AI methods & summary of precision medicine initiatives
In July 2026, Canada’s Drug Agency (CDA) published Use of Artificial Intelligence Methods to Generate Real-World Evidence Submitted to Canada’s Drug Agency for HTA. This guidance document describes pr...Read More -
PMPRB consults further on revised proposed practice directions
The Patented Medicine Prices Review Board (PMPRB) holds public hearings on two types of mattersRead More
